Responses

Download PDFPDF
The successful use of the nasopharyngeal airway in Pierre Robin sequence: an 11-year experience
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Comment on "The successful use of the nasopharyngeal airway (NPA) in Pierre Robin sequence: an 11 year experience" by Abel F, Bajaj Y, Wyatt M, and Wallis C. Arch Dis Child. 2012 Apr;97(4):331-4
    • Emma C. Paes, M.D.
    • Other Contributors:
      • Lucienne Speleman and Corstiaan C. Breugem

    We want to congratulate Abel et al. with their recent publication "The successful use of the nasopharyngeal airway in Pierre Robin sequence: an 11 year experience".

    We do want to make some comments that might be of interest for the reader. First the authors define Robin Sequence (RS) as a triad of micrognathia, glossoptosis and a cleft palate. It has been demonstrated that there is considerable confusion in the...

    Show More
    Conflict of Interest:
    None declared.